Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
A message from Hikma CEO Riad Mishlawi
Latest stories
Featured
Hikma delivers strong 2023 performance and a positive outlook for 2024
Press Release, Financial Results 22 February 2024
- Hikma and Richter announce FDA submission acceptance for Denosumab biosimilar products Press Release, Product 12 December 2024 Hikma and Richter announce FDA submission acceptance for Denosumab biosimilar products
- Hikma launches Furosemide Injection, USP, in the US Press Release, Product 09 December 2024 Hikma launches Furosemide Injection, USP, in the US
- Sell-side analysts and investors visit Hikma Casablanca site Press Release, Corporate 14 November 2024 Sell-side analysts and investors visit Hikma Casablanca site
- Celebrating Global Biosimilars Week: Hikma champions access to essential medicines for patients in the MENA region Story, Business Development 12 November 2024 Celebrating Global Biosimilars Week: Hikma champions access to essential medicines for patients in the MENA region
